Investor Presentation

Date: 26 October 2026 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the investor presentation made by the Company. Thanking you. Yours faithfully, Eris Lifesciences Limited Milind Talegaonkar Company Secretary and Compliance Officer Membership No: A26493 Encl: a/a Q2 & H1 FY27 26th October 2026 Domestic Branded Formulations - DBF International Business Financials Domestic Branded Formulations (DBF) Chronic therapy focused franchise with strong brand building focus ₹ Cr unless specified Therapy Mix (% of revenue) Brands by Annual Revenue (₹ Cr) Revenue Mix by Brand Rank (%) Mother Brand Size No. of brands 200+ 3 Chronic Acute 100-200 3 50-100 11 Sub-chronic 20-50 25 Top 10 brands 11-20 brands Other 86% portfolio is Chronic and Sub-chronic with Top 10 brands contributing to 44% of Sales DBF: Q2 & H1 FY27 Financial Highlights Revenue grew 14.1% YoY in Q2 FY27 with EBITDA margin of 35.7% DBF Revenue (₹ Cr) – Q2 DBF Revenue (₹ Cr) – H1 Zorvia Deal +14.2% +14.1% • Licensed injectables and 809 1,610 part of the Acute portfolio 1,410 to Zorvia Healthcare; Eris retains brand ownership and earns a 7% royalty Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 • These brands contribute DBF EBITDA (₹ Cr) and Margin (%) – Q2 DBF EBITDA (₹ Cr) and Margin (%) – H1 ~₹100 cr of sales EBITDA margin: 37.6% → 35.7% -191 bps EBITDA margin: 37.4% → 35.2% -217 bps +8.3% +7.5% • Ex-Zorvia, Q2 DBF growth is 16.5% 266 527 • Ex Zorvia, going forward, we expect ~100 bps Gross Margin improvement Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 DBF EBIDTA slightly ahead of guidance in Q2 Source – Unaudited Financial Results Pharmarack JAS’26 Data Sequential Improvement in Gross Margin DBF Gross Margin (%) – Q1 vs Q2 FY27 Insulin Pack Shots from Eris Bionxt’s Bhopal Facility +134 bps 74.3% 75.7% Q1 FY27 Q2 FY27 Gross Margin ahead of guidance in Q2 Gross Margin Levers Ahead +100 bps Brands out-licensed to Zorvia Gain Further gross margin gain expected from the out-licensed portfolio expected +100 bps Bhopal facility commercialized Gain Vials and Cartridges now in production expected Full manufacturing shift to Bhopal Next year Complete shift expected in the second half of next year Source – Unaudited Financial Results 5 Eris vs IPM Growth Q2 FY27 Eris Consol OAD Cardiac VMN +3 % +1 % +0 % +10 % 15% 27% 12% 16% 16% IPM Eris IPM Eris IPM Eris IPM Eris All major therapies in Q2 have outgrown the market Ex-Zorvia Eris growth is 17%. Source – Pharmarack JAS’26 Data 6 Diabetes as a Therapy Q2 FY27 Diabetes Contribution to Portfolio Q2 Growth of Diabetes Diabetes Pipeline +2.4 % • Received the nod to conduct Phase 1 and 37.3% Phase 3 trials for India’s first Recombinant 18.5% Semaglutide • Both Drug substance and Drug product for Recombinant Semaglutide from inhouse 16.1% R&D and manufacturing 9.5% • Three more analogs going in the regulatory pathway from Dec-Mar this financial year IPM Eris IPM Eris Diabetes has emerged stronger after Insulins and Semaglutide launches We also have the strongest pipeline of products going ahead in diabetes Source – Pharmarack JAS’26 Data 7 DBF P&L Statement Q2 & H1 FY27 ₹ Cr unless specified Highlights – H1 FY27 DBF (Rs. Cr) Q2 FY27 Q2 FY26 YoY (%) H1 FY27 H1 FY26 YoY (%) Revenue from Operations 809 708 14.1% 1,610 1,410 14.2% ▪ DBF Debtor days at 61 in Sep’ FY27 Gross Profit 612 539 13.5% 1,207 1,078 12.0% against 74 days in Mar’ FY26, a reduction Gross Margin 75.7% 76.1% 75.0% 76.4% of 13 days Employee Cost 137 129 6.1% 284 264 7.3% ▪ Exceptional Items as % of Revenue 16.9% 18.2% 17.6% 18.7% Other Expenses 187 144 29.8% 357 287 24.6% ▪ *Receivables write-off of Rs. ~36 cr as % of Revenue 23.1% 20.3% 22.2% 20.3% of at-risk products only EBITDA 288 266 8.3% 567 527 7.5% EBITDA Margin 35.7% 37.6% 35.2% 37.4% ▪ **Company has received NCLT order Depreciation 14 10 37.9% 28 20 37.6% for merger between its subsidiaries Amortisation 57 57 - 113 113 - Aprica, Eris Oaknet and ETL. Group Finance Cost 46 50 -8.0% 91 98 -6.8% has a positive tax impact of Rs. 65 cr Other Income 2 1 - 5 2 - due to the NCLT order Profit Before Tax after JV 173 151 15.1% 338 298 13.2% Exceptional Items* 36 - - 36 - - Taxes** -33 31 - -1 63 - Profit After Tax (PAT) 170 119 42.7% 303 235 28.9% PAT Margin 21.1% 16.9% 18.8% 16.7% Source – Unaudited Financial Statement 8 Domestic Branded Formulations - DBF International Business Financials Swiss Parenterals – Q2 & H1 FY27 Base business largely uninterrupted; EU CAPA actions underway Revenue (₹ cr)* Key business updates for Q2 2.3% EU CAPA CDMO pipeline Flat 152 155 Execution on track; shutdown planned Current opportunities intact; no in Q3 cancellations 83 83 Base Business Top 10 countries Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Business intact, steady and protected Contribute 50% + of export revenues EBITDA Margin (%) 33.0% 32.8% New Unit III block at Swiss 25.0% 24.9% • Construction on track; PV batches by Apr 27 • Lines planned: PFS, Vials, Lyophilized and Cartridges (incl. Dual Chamber) Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Source – Unaudited Financial Statements * After adjusting for intra-group transactions Domestic Branded Formulations - DBF International Business Financials Summary of Consolidated Financials – Q2 and H1 FY27 Q2 revenue growth of 12.6% with a PAT growth of 39.2% ₹ Cr unless specified Revenue (Rs. Cr.) EBITDA (Rs. Cr.) PAT (Rs. Cr.) 12.8% 7.2% 27.3% 1,766 12.6% 1,565 7.3% 565 606 39.2% 892 187 792 288 309 134 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 Revenue = Rs. 892 cr. – growth of 12.6% yoy • H1 OCF = 105% of EBIDTA Q2 EBIDTA = Rs. 309 cr. – 34.7% EBIDTA margin and 7.3% growth yoy • H1 Capex = Rs. 220 cr. Q2 PAT = Rs. 187 cr. – up 39.2% yoy; Adjusted PAT of Rs. 158 cr. – up • H1 Effective Tax Rate = 20.4% 17.5% yoy Source – Unaudited Financial Statement 12 Consolidated P&L Statement Q2 & H1 FY27 ₹ Cr unless specified Consolidated (Rs. Cr) Q2 FY27 Q2 FY26 YoY (%) H1 FY27 H1 FY26 YoY (%) Highlights – H1 FY27 Revenue from Operations 892 792 12.6% 1,766 1,565 12.8% Gross Profit 667 590 13.0% 1,301 1,178 10.4% ▪ ROCE for FY27 YTD at 19% against 16% in Gross Margin 74.7% 74.5% 73.7% 75.3% FY26 Employee Cost 149 137 8.5% 303 282 7.4% Levers for further ROCE Improvement as % of Revenue 16.7% 17.3% 17.1% 18.0% Other Expenses 208 164 26.6% 392 332 18.4% ▪ Capex cycle is winding down by end of as % of Revenue 23.3% 20.7% 22.2% 21.2% FY27 EBITDA 309 288 7.3% 606 565 7.2% ▪ Three major capital investments - Eris EBITDA Margin 34.7% 36.4% 34.3% 36.1% Bionxt, Swiss and Levim - are yet to Depreciation 17 12 36.8% 32 26 21.2% contribute; returns expected from next Amortisation 57 57 - 113 113 - Finance Cost 46 50 -6.3% 93 98 -5.3% year Other Income 3 3 13.9% 6 6 1.6% ▪ Net Debt reduction of ~111 cr in H1 Profit Before Tax after JV 192 173 11.1% 371 334 11.2% ▪ Consol Debtor days at 70 in Sep’ FY27 Exceptional Items 36 - - 36 - - Taxes -31 38 - 5 74 - against 80 days in Mar’ FY26, a reduction of Effective Tax Rate^ 20.4% 22.1% 20.4% 22.2% 10 days Profit After Tax (PAT) 187 134 39.2% 330 260 27.3% ▪ EPS of Rs. 13.26 in Q2 and Rs. 23.54 in H1 PAT Margin 21.0% 17.0% 18.7% 16.6% ▪ Adj EPS of Rs. 11.16 in Q2 and Rs. 21.44 in H1 Adjusted PAT 158 134 17.5% 301 260 16.1% Adjusted PAT Margin 17.7% 17.0% 17.1% 16.6% Source – Unaudited Financial Statements ^Tax rate is calculated excluding the impact of merger; ROCE = EBIT/ Capital Employed (Total Assets - Current Liabilities) Shareholder Profile As of Sept 2026 Shareholding of Promoters and Top 15 Institutional Investors Shareholding Pattern as of Sept 30, 2026 30-Sept-26 30-June-26 31-Mar-26 Public, Others, Name of Sharehold [Showing first 8,000 characters — download PDF for full document]